Literature DB >> 24123916

The effect of human chorionic gonadotropin-based hormonal therapy on intratesticular testosterone levels and spermatogonial DNA synthesis in men with non-obstructive azoospermia.

E Shinjo1, K Shiraishi, H Matsuyama.   

Abstract

The use of hormonal therapy in men with non-obstructive azoospermia (NOA) is controversial because no information is available on how it affects intratesticular testosterone (ITT) levels and spermatogenic cells. The aim of this study was to investigate the ITT level and spermatogonial DNA synthesis, as determined by proliferating cell nuclear antigen (PCNA) expression, before and after human chorionic gonadotropin (hCG)-based hormonal therapy in men with NOA. Twenty patients who failed sperm retrieval procedures using microdissection testicular sperm extraction (micro-TESE) were enrolled in hCG-based hormonal therapy prior to a second micro-TESE. The patients' ITT levels were determined from testicular fluid obtained during the micro-TESE. Spermatogonial PCNA expression was determined by immunohistochemical analysis, and the PCNA labelling index (PCNA-LI) was calculated. During the second micro-TESE, spermatozoa were successfully retrieved from three (15%) of the men who had been treated with hormonal therapy. PCNA-positive cells were predominantly in the spermatogonia and primary spermatocytes, and PCNA-LI was significantly increased after the hormonal therapy. A significant increase in the ITT levels before and after the hormonal therapy (p < 0.0001, 273.6 ± 134.4 and 1348.1 ± 505.4 ng/mL respectively). The sperm-positive group showed a significantly lower basal ITT level compared with the sperm-negative group (p < 0.05). There was a marked increase in the PCNA-LI levels of men treated with both recombinant human follicle-stimulating hormone and hCG. In addition, there was a significant negative association between the increase in PCNA-LI and basal ITT levels at the initial micro-TESE (p < 0.05), but not the stimulated ITT level at the second micro-TESE. HCG-based hormonal therapy significantly raises the ITT level and stimulates spermatogonial DNA synthesis, potentially improving spermatogenesis. ITT optimization plays, at least in part, an important role for stimulating spermatogenesis in men with NOA.
© 2013 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  hormonal therapy; intratesticular testosterone; non-obstructive azoospermia; proliferative cell nuclear antigen; sperm retrieval

Mesh:

Substances:

Year:  2013        PMID: 24123916     DOI: 10.1111/j.2047-2927.2013.00141.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  14 in total

1.  Successful testicular sperm recovery and IVF treatment in a man with Leydig cell hypoplasia.

Authors:  M E Bakircioglu; P Tulay; N Findikli; B Erzik; M Gultomruk; M Bahceci
Journal:  J Assist Reprod Genet       Date:  2014-05-03       Impact factor: 3.412

Review 2.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

3.  Testicular histology may predict the successful sperm retrieval in patients with non-obstructive azoospermia undergoing conventional TESE: a diagnostic accuracy study.

Authors:  Ettore Caroppo; Elisabetta M Colpi; Giacomo Gazzano; Liborio Vaccalluzzo; Fabrizio I Scroppo; Giuseppe D'Amato; Giovanni M Colpi
Journal:  J Assist Reprod Genet       Date:  2016-09-21       Impact factor: 3.412

Review 4.  Hormonal therapy for non-obstructive azoospermia: basic and clinical perspectives.

Authors:  Koji Shiraishi
Journal:  Reprod Med Biol       Date:  2014-09-18

Review 5.  Management of non-obstructive azoospermia.

Authors:  Koji Chiba; Noritoshi Enatsu; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2016-01-18

Review 6.  Novel concepts in male factor infertility: clinical and laboratory perspectives.

Authors:  Sandro C Esteves
Journal:  J Assist Reprod Genet       Date:  2016-07-16       Impact factor: 3.412

7.  The Effect of Human Chorionic Gonadotropin Therapy on Semen Parameters and Pregnancy Rate after Varicocelectomy.

Authors:  Javanmard Babak; Fadavi Behruz; Yousefi Mohammadreza; Fallah-Karkan Morteza
Journal:  Curr Urol       Date:  2017-12-30

8.  Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients - A proof of concept study.

Authors:  Rita Jakubcionyte Laursen; Birgit Alsbjerg; Helle Olesen Elbaek; Betina Boel Povlsen; Kirsten Brock Spanggaard Jensen; Jette Lykkegaard; Sandro C Esteves; Peter Humaidan
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 3.050

Review 9.  Clinical management of infertile men with nonobstructive azoospermia.

Authors:  Sandro C Esteves
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

10.  SARS-CoV-2 pandemic and repercussions for male infertility patients: A proposal for the individualized provision of andrological services.

Authors:  Sandro C Esteves; Francesco Lombardo; Nicolás Garrido; Juan Alvarez; Armand Zini; Giovanni M Colpi; Jackson Kirkman-Brown; Sheena E M Lewis; Lars Björndahl; Ahmad Majzoub; Chak-Lam Cho; Pedro Vendeira; Jorge Hallak; Edouard Amar; Marcello Cocuzza; Fabiola C Bento; Rita C Figueira; Romualdo Sciorio; Rita J Laursen; Ahmad M Metwalley; Sunil K Jindal; Sijo Parekattil; Ranjith Ramasamy; Carlo Alviggi; Peter Humaidan; John L Yovich; Ashok Agarwal
Journal:  Andrology       Date:  2020-05-22       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.